Mymetics Corp (MYMX)

[Work Harder]

Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review

Int J Biol Macromol. 2021 Jul 1; 182: 648–658.
Published online 2021 Apr 16. doi: 10.1016/j.ijbiomac.2021.04.005


Recently, Great efforts were made to fabricate a virosome-based vaccine platform against a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Thus, this review provides a novel overview of the virosome based nanovaccine production, properties, and application on the viral disease, especially its importance in SARS-CoV-2 vaccine discovery.


This technology is of great importance in developing countries where adequate cooling equipment could not be provided for long time vaccine storage [57].

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049750/#bb0285

57. Amacker M., Smardon C., Mason L., Sorrell J., Jeffery K., Adler M., Bhoelan F., Belova O., Spengler M., Punnamoottil B., Schwaller M., Bonduelle O., Combadière B., Stegmann T., Naylor A., Johnson R., Wong D., Fleury S. New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes. npj Vaccines. 2020;5(1):41.
[PubMed] [Google Scholar]


Respiratory Syncytial Virus (RSV) Virosomes, HA, NA, RSV fusion proteins Under GMP8 IM [58]

58. Lederhofer J., van Lent J., Bhoelan F., Karneva Z., de Haan A., Wilschut J.C., Stegmann T. Development of a Virosomal RSV vaccine containing 3D-PHAD® adjuvant: formulation, composition, and long-term stability. Pharm. Res. 2018;35(9) [PMC free article] [PubMed] [Google Scholar]

Also, the P1 peptide improves the function and movement of protein epitopes. 3 m-052 adjuvants help develop long-lasting immunity confronting HIV-1 viruses, incorporated via 18 carbon fatty-acid chain into virosome phospholipid bilayer. 3 m-052 is a thermostable adjuvant that increased virosome membrane rigidity [78,79].

79. Wong Y.T., Smardon C., Shirkhani K., Amacker M., Fleury S., Stegmann A.J.H. Oral dispersible vaccine comprising virosomes. US Patent App. 2020;16(/696):752. [Google Scholar]

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163253848

Catalent